These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 30055238

  • 21. Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns.
    Tan S, Zhang H, Zhang Y, Chen W, D'Souza WD, Lu W.
    Med Phys; 2013 Oct; 40(10):101707. PubMed ID: 24089897
    [Abstract] [Full Text] [Related]

  • 22. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.
    Zhang H, Tan S, Chen W, Kligerman S, Kim G, D'Souza WD, Suntharalingam M, Lu W.
    Int J Radiat Oncol Biol Phys; 2014 Jan 01; 88(1):195-203. PubMed ID: 24189128
    [Abstract] [Full Text] [Related]

  • 23. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
    Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1053-9. PubMed ID: 15964705
    [Abstract] [Full Text] [Related]

  • 24. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
    Yuan H, Tong DK, Vardhanabhuti V, Law SY, Chiu KW, Khong PL.
    Nucl Med Commun; 2016 Sep 15; 37(9):947-55. PubMed ID: 27145438
    [Abstract] [Full Text] [Related]

  • 25. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
    Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA.
    J Clin Oncol; 2004 Mar 01; 22(5):900-8. PubMed ID: 14990646
    [Abstract] [Full Text] [Related]

  • 26. Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy.
    Nakajo M, Jinguji M, Nakabeppu Y, Nakajo M, Higashi R, Fukukura Y, Sasaki K, Uchikado Y, Natsugoe S, Yoshiura T.
    Eur J Nucl Med Mol Imaging; 2017 Feb 01; 44(2):206-214. PubMed ID: 27613542
    [Abstract] [Full Text] [Related]

  • 27. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
    Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, Corcos L, Visvikis D.
    J Nucl Med; 2011 Mar 01; 52(3):369-78. PubMed ID: 21321270
    [Abstract] [Full Text] [Related]

  • 28. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
    Li Y, Zschaeck S, Lin Q, Chen S, Chen L, Wu H.
    Radiat Oncol; 2019 Feb 19; 14(1):35. PubMed ID: 30782182
    [Abstract] [Full Text] [Related]

  • 29. 18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy.
    Lee S, Choi Y, Park G, Jo S, Lee SS, Park J, Shim HK.
    Technol Cancer Res Treat; 2021 Feb 19; 20():15330338211024655. PubMed ID: 34227434
    [Abstract] [Full Text] [Related]

  • 30. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW, Koong AC, Chang DT.
    Int J Radiat Oncol Biol Phys; 2012 Oct 01; 84(2):471-7. PubMed ID: 22381904
    [Abstract] [Full Text] [Related]

  • 31. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K.
    Eur J Radiol; 2018 Apr 01; 101():65-71. PubMed ID: 29571803
    [Abstract] [Full Text] [Related]

  • 32. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 01; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 33. Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
    Kaderi ASA, Sabita J, Tiwari VK, Pawar A, Niyogi D.
    J Gastrointest Cancer; 2024 Jun 01; 55(2):820-828. PubMed ID: 38308686
    [Abstract] [Full Text] [Related]

  • 34. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
    Cong L, Wang S, Gao T, Hu L.
    Jpn J Clin Oncol; 2016 Dec 01; 46(12):1118-1126. PubMed ID: 27702836
    [Abstract] [Full Text] [Related]

  • 35. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):358-63. PubMed ID: 17532577
    [Abstract] [Full Text] [Related]

  • 36. Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study.
    Domachevsky L, Kashtan H, Brenner B, Nidam M, Morgenstern S, Kundel Y, Groshar D, Bernstine H.
    Medicine (Baltimore); 2018 Dec 01; 97(49):e13412. PubMed ID: 30544419
    [Abstract] [Full Text] [Related]

  • 37. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
    Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M.
    Ann Surg; 2001 Mar 01; 233(3):300-9. PubMed ID: 11224616
    [Abstract] [Full Text] [Related]

  • 38. Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
    Collarino A, Feudo V, Pasciuto T, Florit A, Pfaehler E, de Summa M, Bizzarri N, Annunziata S, Zannoni GF, de Geus-Oei LF, Ferrandina G, Gambacorta MA, Scambia G, Boellaard R, Sala E, Rufini V, van Velden FH.
    J Nucl Med; 2024 Jun 03; 65(6):962-970. PubMed ID: 38548352
    [Abstract] [Full Text] [Related]

  • 39. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer.
    Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K.
    Am J Clin Oncol; 2018 Mar 03; 41(3):254-258. PubMed ID: 26703814
    [Abstract] [Full Text] [Related]

  • 40. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D.
    J Nucl Med; 2013 Jan 03; 54(1):19-26. PubMed ID: 23204495
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.